Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting

SOUTH SAN FRANCISCO, CA, December 6, 2025 – Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced interim data from its ongoing Phase 1/2 multidose… The post Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting appeared first on STAR Therapeutics .